Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research note issued to investors on Friday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Down 5.4 %

Shares of NASDAQ GLMD opened at $1.59 on Friday. Galmed Pharmaceuticals has a 12-month low of $1.38 and a 12-month high of $23.80. The firm’s 50-day simple moving average is $2.37 and its 200 day simple moving average is $3.36. The company has a market cap of $1.02 million, a price-to-earnings ratio of -0.10 and a beta of 0.72.

Institutional Investors Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is owned by institutional investors and hedge funds.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.